Revenue growth has strengthened to +21% to the end of April, driven by an ahead of expectations performance from the Research segment. Having updated our forecasts last month, we make no further changes at this stage, but will review these again at the H1 update in July. It is gratifying the business has continued to perform strongly during the inevitable distractions of recent months. We continue to see a substantial growth runway ahead as FeNO testing becomes more widely adopted. NIOX is a hig ....
